Recombinant Vaccines Research Report 2024: Market Poised for Accelerated Growth, Set to Reach $34.18 Billion by 2034 from $10.14 Billion in 2023
January 31, 2024 11:23 ET
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Recombinant Vaccines Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global...
H1N1 Vaccines Industry Report 2023-2028: North America Leads Charge with Advanced Vaccine Research and Public Health Initiatives
January 29, 2024 07:41 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "H1N1 Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ResearchAndMarkets.com's...
Global Therapeutic BCG Vaccine Market Analysis Report 2023-2028: Increasing Tuberculosis Control Efforts Driving Industry Growth
January 26, 2024 07:34 ET
|
Research and Markets
Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Therapeutic BCG Vaccine Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F" report has been added to ...
Plant-based Vaccines Market Industry Analysis and Forecast to 2031 - Promising Avenue for Safer, More Accessible and Cost-Effective Vaccine Development
January 25, 2024 14:11 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Plant-based Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application,...
COVID-19 Vaccines Global Market Outlook to 2026: Trends & Analysis, Epidemiology, Unmet Needs & Opportunities, Therapeutic Landscape, Pipeline Assessment, Clinical Trial Strategies
January 23, 2024 16:03 ET
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "COVID-19 Vaccines Market Size, Trends and Analysis by Disease Overview, Epidemiology, Unmet Needs and Opportunities, Therapeutic Landscape, Pipeline...
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
January 18, 2024 07:00 ET
|
HilleVax, Inc.
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
January 08, 2024 07:00 ET
|
HilleVax, Inc.
BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and...
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 18:28 ET
|
HilleVax, Inc.
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Quadrivalent Virus-Like Particle (VLP) Vaccine Emerging Drug Insights and Market Forecasts, 2019-2022 and 2023-2032
December 14, 2023 10:03 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Quadrivalent VLP vaccine Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...
ELISpot and FluoroSpot Assay Market is Expected to Reach $421 million | MarketsandMarkets.
December 04, 2023 07:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Dec. 04, 2023 (GLOBE NEWSWIRE) -- ELISpot and FluoroSpot Assay market in terms of revenue was estimated to be worth $292 million in 2023 and is poised to reach $421 million by 2028, growing...